Profile of BIOMX INC(NYSEARCA:PHGE) stock

BIOMX INC0.3799

NYSEARCA:PHGE (2/3/2023, 7:04:01 PM)0 (-0.96%)

After market: 0.3799 0 (0%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Health Care
GICS Industry	Biotechnology

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	11-09 2022-11-09/bmo	Earnings (Next)	05-09 2023-05-09/amc
Ins Owners	N/A	Inst Owners	20.55%
Market Cap	11.39M	Shares	29.98M
PE	N/A	Fwd PE	N/A
Dividend Yield	N/A	Analysts	84
IPO	12-18 2018-12-18

Stock Screener Links

American Stock Exchange Stock Screener

Find more stocks on American Stock Exchange

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

BiomX, Inc. operates as a clinical-stage microbiome company. The firm is focused on developing both natural and engineered phage therapies. The company develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The firm discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

Company Info

BIOMX INC

22 Einstein St., Floor 5

Ness Ziona 7414002

P: 972723942377.0

CEO: Jonathan Solomon

Employees: 103

Website: https://www.biomx.com/

PHGE News

16 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's the final day of trading this week and we're checking in on the biggest pre-market stock movers for Friday morning!

2 months ago - BiomXBiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

NESS ZIONA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company...

3 months ago - BiomXBiomX Reports Third Quarter 2022 Financial Results and Provides Business Update

Continued Progress Enrolling Patients in Phase 1/2 Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis; Results from Part 1 of the Trial Now...

3 months ago - BiomXBiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022

NESS ZIONA, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company...

4 months ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, investor! We're starting off Thursday with a breakdown of the biggest pre-market stock movers this morning!